07630.HK
IMPACT THERAP-B
HKSE · Healthcare · Drug Manufacturers - General · CN
HKD 8.51
−11.36%Year over year
Reported trailing growth
- Revenue
- +396.5%
- EBITDA
- -10.4%
- EBIT
- -7.9%
- EPS
- +20.0%
- Free cash flow
- -42.1%
- Operating cash flow
- -47.4%
Forward estimates
Based on analyst estimates
- Revenue
- +2309.0%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -60.0%
- EBITDA
- -16.9%
- EBIT
- -10.5%
- Net income
- -16.0%
- EPS
- +16.7%
- Free cash flow
- -10.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026